 SAN FRANCISCO and SAN DIEGO, May 13, 2021 GLOBE NEWSWIRE -- Kinnate Biopharma Inc. Nasdaq: KNTE Kinnate, a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of a 35 million Series A financing for a joint venture in China. Established with OrbiMed Asia Partners, OrbiMed Private Investments and Foresite Capital, the joint venture will be headquartered in Shanghai and enable the potential development and commercialization of certain Kinnate targeted oncology product candidates across Greater China mainland China, Hong Kong, Taiwan, and Macau. Kinnate Biopharma will be the majority shareholder in the joint venture. The company has also announced that veteran biopharmaceutical industry executive Wenn Sun, Ph.D., has been appointed as the joint ventures Executive Chair. 